<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24306" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Lipid-Lowering Drug Therapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chhetry</surname>
            <given-names>Minar</given-names>
          </name>
          <aff>NewYorkPresbyterian/Queens</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jialal</surname>
            <given-names>Ishwarlal</given-names>
          </name>
          <aff>VA MEDICAL CENTER, MATHER , CA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Minar Chhetry declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24306.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Patients at an increased risk of cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina) benefit from lipid-lowering medications. It is essential to recognize that these drugs are useful in combination with lifestyle modification. These medications can be used for primary or secondary prevention of cardiovascular events. This activity covers lipid-lowering pharmaceutical interventions that members of the interprofessional team need to review the indications, contraindications, and adverse event profiles to optimally manage patients with abnormal lipid profiles and direct care to optimal outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanisms of action of the most prominent lipid-lowering pharmaceutical agents.</p></list-item><list-item><p>Explain the indications for using the various agents in the lipid-lowering therapy family of medications.</p></list-item><list-item><p>Review the adverse effect profile of various individuals lipid-lowering therapy agents.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and communication to properly use lipid-lowering medications to improve patient outcomes in the varied scenarios where lipid-lowering pharmaceutical therapy can be used.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24306&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24306">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24306.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Atherosclerosis is one of the major causes of coronary heart disease. According to the 2016 CDC data, heart disease is the leading cause of death in the United States. Dietary modifications, weight reduction, and exercise are the first line of defense. Patients at an increased risk of cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina) benefit from lipid-lowering medications. It is essential to understand that these drugs are useful in combination with lifestyle modification. These medications can be used for primary or secondary prevention of cardiovascular events. Primary prevention includes patients without prior events but with risk&#x000a0;factors such as diabetes mellitus and hypertension. Secondary prevention includes patients with a history of cardiovascular events. The 2018 ACC/AHA guideline emphasizes reducing the risk of ASCVD (atherosclerotic cardiovascular disease) through lipid management.<xref ref-type="bibr" rid="article-24306.r1">[1]</xref>&#x000a0;Lipoprotein modifying agents encompass several classes of drugs, including hydroxymethylglutaryl (HMG) CoA reductase inhibitors (statins), cholesterol absorbing inhibitors, fibric acid derivatives, bile acid sequestrants, PCSK9 inhibitors, and nicotinic acid.&#x000a0;</p>
        <p><bold>Statins:&#x000a0;</bold>They are the first line of lipid-lowering drugs, while others, discussed subsequently, are added to increase the efficiency of statins or in cases of statin intolerance or cases of severe hypertriglyceridemia. Statins can lower low-density lipoprotein (LDL) and triglyceride concentrations (at higher doses) while increasing high-density lipoprotein (HDL) concentrations.</p>
        <p><bold>Ezetimibe:&#x000a0;</bold>Ezetimibe impairs cholesterol absorption and lowers LDL-C, apolipoprotein B (apo B), and non-HDL in patients with primary hyperlipidemia, mixed hyperlipidemia, and familial hypercholesterolemia (FH).<xref ref-type="bibr" rid="article-24306.r2">[2]</xref></p>
        <p><bold>Fibrates:&#x000a0;</bold>Fibrates are known to&#x000a0;decrease triglycerides by as much as 50 percent and also raise HDL by 5 to 20 percent.<xref ref-type="bibr" rid="article-24306.r3">[3]</xref>&#x000a0;Fibrates, despite their effects on lipids, have less favorable effects on clinical outcomes.<xref ref-type="bibr" rid="article-24306.r4">[4]</xref>&#x000a0;They are primarily used to lower triglycerides to avert the risk of pancreatitis.</p>
        <p><bold>Nicotinic Acid:&#x000a0;</bold>Nicotinic acid (niacin) raises high-density lipoprotein cholesterol (HDL-C) significantly, but this has not been shown to improve patient outcomes in patients on statins.<xref ref-type="bibr" rid="article-24306.r5">[5]</xref><xref ref-type="bibr" rid="article-24306.r6">[6]</xref>&#x000a0;Niacin&#x000a0;use can help lower LDL in combination with statins plus ezetimibe in patients at extremely&#x000a0;high cardiovascular risk, such as homozygous or heterozygous familial hypercholesterolemia, but not in secondary prevention.</p>
        <p><bold>Bile Acid Sequestrants(BAS):&#x000a0;</bold>Bile acid sequestrants include cholestyramine, colestipol, and colesevelam. Bile acids sequestrants are indicated for primary hypercholesterolemia, usually in combination with statins or nicotinic acid. Cholestyramine has&#x000a0;been shown to decrease cardiovascular mortality and morbidity by 19% compared to placebo in patients and benefit patients with Type 2 DM by decreasing blood sugar levels.<xref ref-type="bibr" rid="article-24306.r7">[7]</xref>&#x000a0;Bile acid sequestrants can also rapidly reduce plasma thyroid hormones, thus making them useful for refractory thyrotoxicosis.<xref ref-type="bibr" rid="article-24306.r8">[8]</xref> They can also raise HDL-C.<xref ref-type="bibr" rid="article-24306.r9">[9]</xref><xref ref-type="bibr" rid="article-24306.r10">[10]</xref><xref ref-type="bibr" rid="article-24306.r11">[11]</xref>&#x000a0;They can be used to manage pruritus in patients with cholestatic disease and incomplete biliary obstruction.</p>
        <p><bold>PCSK9 Inhibitors:</bold> Proprotein convertase&#x000a0;subtilisin/kexin&#x000a0;type 9(PCSK9) inhibitors&#x000a0;are a new group of drugs approved to lower LDL and have been shown to lower LDL by as much as 60 percent in patients taking statins. FDA has approved alirocumab and evolocumab for adult patients with heterozygous familial hypercholesterolemia or clinical ASCVD who require further lowering of LDL-cholesterol in addition to diet modification and maximally tolerated statin therapy. FDA has also approved evolocumab for adult patients with homozygous familial hypercholesterolemia who require further lowering of LDL-C in addition to other LDL-lowering therapies like statins or ezetimibe.&#x000a0;</p>
      </sec>
      <sec id="article-24306.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Statins are competitive inhibitors of hydroxymethylglutaryl (HMG) CoA reductase,&#x000a0;an enzyme that participates in a crucial rate-limiting step in cholesterol biosynthesis.<xref ref-type="bibr" rid="article-24306.r12">[12]</xref>&#x000a0;This enzymatic inhibition increases low-density lipoprotein (LDL) clearance from the serum by the upregulation of LDL receptors on the liver.<xref ref-type="bibr" rid="article-24306.r13">[13]</xref>&#x000a0;Statins can also reduce very-low-density lipoprotein (VLDL) by an effect hepatic apolipoprotein B secretion.<xref ref-type="bibr" rid="article-24306.r14">[14]</xref> Statins have a modest effect on increasing high-density lipoprotein (HDL) and can also reduce triglycerides levels depending upon the statin and the dose used. Statins can lower LDL cholesterol by up to 63%.<xref ref-type="bibr" rid="article-24306.r15">[15]</xref><xref ref-type="bibr" rid="article-24306.r16">[16]</xref>&#x000a0;Rosuvastatin and atorvastatin are high-intensity statins, with rosuvastatin being slightly more potent than atorvastatin.<xref ref-type="bibr" rid="article-24306.r17">[17]</xref>&#x000a0;Statins can also lower triglycerides (TG), especially if the TG level is greater than 250 mg/dl.<xref ref-type="bibr" rid="article-24306.r18">[18]</xref></p>
        <p>Ezetimibe impedes dietary and biliary cholesterol absorption at the brush border of the intestine without increasing bile acid excretion or inhibiting cholesterol synthesis in the liver. It inhibits Nieman-Pick C1 like 1(NPC1L1) protein, which is present in both the intestine and the liver.<xref ref-type="bibr" rid="article-24306.r19">[19]</xref><xref ref-type="bibr" rid="article-24306.r20">[20]</xref>&#x000a0;This leads to a decrease in the delivery of cholesterol to the liver, an increase in cholesterol clearance from the blood, and a reduction in hepatic cholesterol stores.</p>
        <p>Fibrates are agonists for the nuclear transcription factor peroxisome proliferator-activated receptor alpha (PPAR-alpha). This receptor downregulates apoprotein C-III (an inhibitor of lipoprotein lipase) while upregulating the synthesis of apolipoprotein A-I, lipoprotein lipase, and fatty acid transport protein, resulting in an increase in VLDL catabolism and elimination of triglyceride-rich particles; this results in lowering of total plasma triglycerides by 30% to 60%; also a modest increase in HDL has been observed.&#x000a0;</p>
        <p>The mechanism by which nicotinic acid affects plasma lipoproteins is not fully known. It may involve several mechanisms, including partial inhibition of free fatty acid release from adipose tissue and increased lipoprotein lipase action, which may increase the rate of triglyceride removal from plasma.&#x000a0;</p>
        <p>Bile acid sequestrants bind with bile acids in the intestines, thus interrupting the reabsorption of bile acids. The ensuing reduction in the cholesterol pool lowers intrahepatic cholesterol, promoting the upregulation of LDL receptors, causing a further decrease in blood cholesterol. The bile acid sequestrants also induce a minimal elevation in high-density lipoprotein cholesterol (HDL-C).<xref ref-type="bibr" rid="article-24306.r21">[21]</xref>&#x000a0;BAS can reduce LDL starting at 15 percent and up by 24 percent at the maximal recommended dose.<xref ref-type="bibr" rid="article-24306.r22">[22]</xref>&#x000a0;They can raise triglyceride levels and should not be used if TG is greater than 400 mg/dl.&#x000a0;</p>
        <p>PCSK9 binds to the low-density lipoprotein receptor (LDL-R) on the surface of hepatocytes leading to the targeted degradation of LDL-R &#x000a0;by lysosomes and, ultimately, an increase in plasma LDL-cholesterol (LDL-C) levels. Antibodies to PCSK9 interfere with its binding of the LDL-R, leading to higher hepatic LDL-R expression and lower plasma LDL-C levels.<xref ref-type="bibr" rid="article-24306.r23">[23]</xref></p>
      </sec>
      <sec id="article-24306.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Most cholesterol synthesis occurs at night, reflecting the fasting state. Thus, prompting the statins to be administered at evening or bedtime.<xref ref-type="bibr" rid="article-24306.r24">[24]</xref> Some studies have suggested every other day regimen of statin to reduce cost and improve the tolerability of statins while major outcome trials of statins base their results on daily statin therapy; thus, every other day is not a common practice except in patients unable to tolerate statins.<xref ref-type="bibr" rid="article-24306.r25">[25]</xref><xref ref-type="bibr" rid="article-24306.r26">[26]</xref><xref ref-type="bibr" rid="article-24306.r27">[27]</xref></p>
        <p>Ezetimibe may be taken with meals and can be safely administered along with a statin or a fibrate.&#x000a0;It may be taken at the same time as fenofibrate or HMG-CoA reductase inhibitors, but the recommendation is to take it at least 1 hour before or 4 hours after taking bile acid sequestrants.</p>
        <p>Fibrates dosing is usually 30 minutes before meals.&#x000a0;</p>
        <p>Nicotinic acid is given orally with a meal and usually started at 100 mg three times a day and gradually increased as tolerated to 2.0g/dL.<xref ref-type="bibr" rid="article-24306.r5">[5]</xref>&#x000a0;LDL-C lowering occurs at doses greater than 1.5 g/day.</p>
        <p>Bile acid sequestrants are available as granules or tablets. Cholestyramine should ideally be taken with breakfast when given to treat pruritus associated with cholestasis. Symptoms of pruritus are less frequent in the morning as the belief is that&#x000a0;the pruritogenic factors concentrate in the gallbladder during overnight fasting.</p>
        <p>PCSK9 inhibitors are administered by subcutaneous injections, with enzyme inactivation occurring within four to eight hours. Cost is the primary limiting factor for PCSK9 inhibitors.</p>
      </sec>
      <sec id="article-24306.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Statins are among the safest medications to lower lipids, with muscle injury being the most common injury.<xref ref-type="bibr" rid="article-24306.r28">[28]</xref><xref ref-type="bibr" rid="article-24306.r29">[29]</xref>&#x000a0;Other adverse effects include new-onset diabetes mellitus and hepatotoxicity.</p>
        <p>Lipophilic statins (simvastatin, lovastatin, atorvastatin, and fluvastatin) may be associated with more adverse events than the more hydrophilic statins (pravastatin and rosuvastatin).<xref ref-type="bibr" rid="article-24306.r30">[30]</xref></p>
        <p>
<bold>Muscle Injury</bold>
</p>
        <p>Statin-induced muscle injury can vary from myalgias to rarely myonecrosis or rhabdomyolysis.<xref ref-type="bibr" rid="article-24306.r29">[29]</xref> A meta-analysis of 42 randomized trials of statins found little or no excess risk of myalgias, CK elevations, rhabdomyolysis, or discontinuation of therapy versus placebo; however,&#x000a0;in clinical practice, muscle side effects are relatively common, and the explanation for this difference is uncertain.<xref ref-type="bibr" rid="article-24306.r31">[31]</xref><xref ref-type="bibr" rid="article-24306.r32">[32]</xref> A higher incidence of myalgia was seen in patients treated with atorvastatin 80 mg daily than with a placebo.<xref ref-type="bibr" rid="article-24306.r33">[33]</xref>&#x000a0;Clinically significant myonecrosis, defined as a serum CK elevation over ten times normal, occurred in less than 0.5 percent of patients in large clinical trials.<xref ref-type="bibr" rid="article-24306.r34">[34]</xref><xref ref-type="bibr" rid="article-24306.r35">[35]</xref> Statin-induced myopathy was noted to be worse with higher doses of statins and the sensitivity of statins on striated muscles. Simvastatin and lovastatin have the highest risk of myopathy, while fluvastatin and pravastatin have the&#x000a0;lowest risk.<xref ref-type="bibr" rid="article-24306.r36">[36]</xref>&#x000a0;Patients with pre-existing neuromuscular disease make them prone to muscle injuries such as myasthenia gravis, mitochondrial myopathy, McArdle disease, acid maltase deficiency, and amyotrophic lateral sclerosis (ALS).<xref ref-type="bibr" rid="article-24306.r37">[37]</xref><xref ref-type="bibr" rid="article-24306.r38">[38]</xref></p>
        <p>Research has shown that vigorous exercise in those on statins may increase the risk of muscle injury. Creatine&#x000a0;kinase (CK) is the measure for the diagnosis of severe myositis and myonecrosis. However, many patients will not have an elevation in CK. Thus, routine monitoring of CK is usually not recommended; however, it is useful to get a baseline CK level before initiation of treatment.<xref ref-type="bibr" rid="article-24306.r39">[39]</xref><xref ref-type="bibr" rid="article-24306.r40">[40]</xref><xref ref-type="bibr" rid="article-24306.r41">[41]</xref></p>
        <p>
<bold>Management of Muscle Injury</bold>
</p>
        <p>Strategies include assessing drug interaction, vitamin D deficiency, and hypothyroidism, switching between statins, or a trial of an alternate-day regimen.<xref ref-type="bibr" rid="article-24306.r42">[42]</xref> Coenzyme Q10 appears to benefit patients with muscle events, but there is minimal published evidence showing the benefit of CoQ10.<xref ref-type="bibr" rid="article-24306.r43">[43]</xref>&#x000a0;Further, large-scale studies are necessary to assess the beneficial effects of CoQ10.&#x000a0;</p>
        <p>Ezetimibe can cause fatigue, diarrhea, headache, runny nose, body aches, back pain, chest pain, diarrhea, joint pain, sore throat, and elevation of serum transaminases.&#x000a0;</p>
        <p>Fibrate commonly causes dyspepsia and has also been shown to produce fatigue, vertigo, pancytopenia, and elevation of serum transaminases.</p>
        <p>Nicotinic acid is often poorly tolerated, with flushing occurring in 80 percent of patients,&#x000a0;along with pruritus, paresthesia, and nausea in about 20 percent of patients.<xref ref-type="bibr" rid="article-24306.r44">[44]</xref>&#x000a0;These symptoms can last from 10 to 20 minutes, and pretreatment with aspirin or ibuprofen 60 minutes prior can minimize flushing and other prostaglandin-mediated side effects. Other concerns are hyperglycemia with an increased risk of diabetes mellitus, hyperuricemia, liver dysfunction, hypotension in patients taking vasodilators, increased chances of infection, and bleeding as they decrease platelet function and increase prothrombin time. Nicotinic acid has also&#x000a0;been shown to increase the levels of homocysteine levels.<xref ref-type="bibr" rid="article-24306.r45">[45]</xref><xref ref-type="bibr" rid="article-24306.r46">[46]</xref><xref ref-type="bibr" rid="article-24306.r45">[45]</xref><xref ref-type="bibr" rid="article-24306.r47">[47]</xref></p>
        <p>Bile Acid sequestrants cause gastrointestinal side effects, including nausea, bloating, cramping, and an increase in liver enzymes. Dyspepsia and bloating can be decreased if cholestyramine is completely suspended in liquid several hours before ingestion.&#x000a0;</p>
        <p>PCSK9 inhibitors can cause Local injection site reactions such as erythema, pain, and bruising. Neither muscle toxicity nor creatine kinase elevations have appeared in patients after administering PCSK9 antibodies.<xref ref-type="bibr" rid="article-24306.r48">[48]</xref><xref ref-type="bibr" rid="article-24306.r49">[49]</xref><xref ref-type="bibr" rid="article-24306.r50">[50]</xref></p>
      </sec>
      <sec id="article-24306.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hypersensitivity&#x000a0;reaction, such as anaphylaxis and angioedema, is an absolute contraindication, universal to all lipid-lowering&#x000a0;drugs.&#x000a0;</p>
        <p>Contraindications to statins include use by patients with active hepatic disease or unexplained persistent elevations in aminotransferase levels. Statins are contraindicated in pregnancy and breastfeeding as cholesterol is essential for fetal and infant synthesis of steroids and cell membrane development, although some recent studies question this.<xref ref-type="bibr" rid="article-24306.r51">[51]</xref> Statins demonstrate an increased risk of developing diabetes mellitus; thus, caution is necessary for patients with already increased blood glucose levels or increased Hba1c levels. Drugs that inhibit cytochrome P450 3A4(CYP3A4) can increase the risk of statin-induced myopathy. These include cyclosporine, macrolide antibiotics, system-azole antifungals, HIV/HCV protease inhibitors, gemfibrozil,&#x000a0;diltiazem, verapamil, amiodarone, colchicine, and also&#x000a0;grapefruit juice.<xref ref-type="bibr" rid="article-24306.r52">[52]</xref><xref ref-type="bibr" rid="article-24306.r53">[53]</xref></p>
        <p>Ezetimibe is contraindicated in patients using an HMG-CoA reductase inhibitor (statin) in patients with active liver disease or otherwise unexplained elevated serum transaminase values. Ezetimibe alone is not contraindicated in patients with mild to moderate hepatic impairment. Contraindications to ezetimibe include patients who are pregnant and breastfeeding when used in patients already on statins.&#x000a0;</p>
        <p>Fibrates are contraindicated in those patients with&#x000a0;active liver disease, including primary biliary cirrhosis and unexplained, persistent liver function abnormality; severe renal impairment, and/or end-stage renal disease (ESRD), including patients receiving dialysis; preexisting gallbladder disease; and breastfeeding.</p>
        <p>Nicotinic acid is contraindicated in active hepatic disease or significant persistent elevations of hepatic transaminases. These effects will be amplified when used with statins, fibrates, etc. They are also contraindicated in patients with active peptic ulcers and arterial hemorrhage.</p>
        <p>Bile acid sequestrants are contraindicated in cases of severe hypertriglyceridemia and complete biliary obstruction. Bile acid sequestrants do not get absorbed into the bloodstream, making them safe for use by patients who are unable to use other lipid-lowering medications because of liver problems.</p>
        <p>PCSK9 inhibitors do not cause muscle toxicity or an elevation in hepatic enzymes.&#x000a0;</p>
      </sec>
      <sec id="article-24306.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Practitioners should check the patient's lipid profile within 4 to 8 weeks of starting treatment with follow-up checks every 6 to 12 months to monitor the effectiveness of therapy.&#x000a0;</p>
        <p>In 2006, The National Lipid Association's Statin Task Force&#x000a0;stated that routine monitoring of&#x000a0;liver enzymes in asymptomatic patients is not recommended as the risk of severe liver injury is uncommon.<xref ref-type="bibr" rid="article-24306.r54">[54]</xref>&#x000a0;This ruling was revised in 2012 by the US Food and Drug Administration (FDA) with new labeling rules for statins, recommending instead performing liver enzyme tests before initiating statin therapy and as clinically indicated thereafter.<xref ref-type="bibr" rid="article-24306.r55">[55]</xref> The 2014 task force on statin therapy concluded that "the decision on statin intolerance is the patient's decision, based on subjective feelings, preferences, and judgment," but best when guided "by evaluation and effective communication from the clinician."</p>
        <p>Moderate-intensity therapy is expected to result in an LDL reduction of 30% to 50% from baseline, while a high-intensity regimen can result&#x000a0;in a&#x000a0;reduction of more than 50% from baseline.</p>
        <p>When combining ezetimibe with statins or fenofibrate, monitor LFTs and signs of cholelithiasis. The recommendation is to discontinue the use of ezetimibe if ALT elevations are greater than three times the upper limit of normal persist.<xref ref-type="bibr" rid="article-24306.r56">[56]</xref></p>
        <p>Fibrate use requires monitoring with liver function tests, renal function tests, and CBC due to the risk for pancytopenia.&#x000a0;</p>
        <p>Nicotinic acid needs monitoring of blood sugar, coagulation profile, and liver function.</p>
      </sec>
      <sec id="article-24306.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Rhabdomyolysis is a severe&#x000a0;and potentially fatal complication with statins. The general treatment is supportive and comprises immediate discontinuation of the offending drug. Other supportive measures include correcting any electrolyte disturbances,&#x000a0;especially hyperkalemia, which can cause life-threatening arrhythmias. &#x000a0;</p>
        <p>When used with a statin, ezetimibe can increase the risk of muscle toxicity, especially in&#x000a0;advanced age over 65 years old, renal impairment, or hypothyroidism. Patients taking ezetimibe with cyclosporine are at an increased risk of ezetimibe toxicity as it can result in a 2.3- to 12-fold increase in ezetimibe concentration.<xref ref-type="bibr" rid="article-24306.r57">[57]</xref></p>
        <p>Bile acid sequestrants can inhibit the absorption of fat-soluble vitamins such as vitamin K, which can cause derangements in clotting factors. They can also interfere with the absorption of medications such as statins, ezetimibe, warfarin, NSAIDs, and propranolol; thus, the advice is to administer these medications 1 hour before or 4 hours after taking cholestyramine.<xref ref-type="bibr" rid="article-24306.r58">[58]</xref></p>
      </sec>
      <sec id="article-24306.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The success of lipid-lowering medications to prevent cardiovascular events depends on the patient's medication adherence. It is common for patients to stop taking statins when they start to&#x000a0;experience&#x000a0;muscle aches. It is critical to reiterate the need for patients to continue statins in these situations. Alternatives such as switching to a different statin, adding coenzyme Q10, or an alternate day dosing is an option, which has demonstrated to help to a certain extent.</p>
        <p>Lipid-lowering therapy is best delivered by an interprofessional team consisting of physicians&#x000a0;(both primary care and cardiologist), pharmacist, and cardiovascular specialty trained nursing staff to guide and monitor the therapeutic course and ensure the best possible patient outcomes. [Level V]</p>
        <p>In patients with severe HTG, particularly triglyceride levels greater than 1000 mg/dL, fibrate therapy and/or niacin and fish oil can be useful to lower triglycerides to under 500 mg/dL and to help reduce the risk of pancreatitis. Intravenous insulin can help to prevent pancreatitis in the hospital.<xref ref-type="bibr" rid="article-24306.r59">[59]</xref></p>
        <p>FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) study showed no mortality benefit but lowered the risk of myocardial infarction or stroke.<xref ref-type="bibr" rid="article-24306.r60">[60]</xref>&#x000a0;The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with alirocumab) was able to show a 2% absolute risk reduction in major adverse cardiovascular events with alirocumab therapy.<xref ref-type="bibr" rid="article-24306.r48">[48]</xref></p>
        <p>IMPROVE-IT found in a follow-up of 6 years that patients with an acute coronary syndrome randomized to ezetimibe/simvastatin had a lower rate of cardiovascular events than those randomized to simvastatin alone.<xref ref-type="bibr" rid="article-24306.r61">[61]</xref>&#x000a0;Some studies have also found that adding ezetimibe to atorvastatin 80 mg can further lower the LDC by 9 percent compared to statin alone.<xref ref-type="bibr" rid="article-24306.r62">[62]</xref></p>
        <p>A recent 2018 Reduction of Cardiovascular Events with Icosapent Ethyl&#x02013;Intervention Trial (REDUCE-IT) trial used 2 g of icosapent ethyl twice daily (4 g daily). The patients in the study had established atherosclerotic heart disease or other risk factors such as diabetes and were already on pre-existing statin therapy with residual hypertriglyceridemia (triglyceride level 135 to 499 mg/dL). The intervention group was associated with an absolute 4.8% reduction in cardiovascular events and a 0.9% absolute reduction in cardiovascular death at 4.9 years.<xref ref-type="bibr" rid="article-24306.r63">[63]</xref></p>
        <p>Fish oil (omega-3 fatty acids) is a common supplement used to prevent cardiovascular events, but a recent large randomized controlled study showed no benefit of omega-3 fatty acids&#x000a0;in the incidence of major cardiovascular events.<xref ref-type="bibr" rid="article-24306.r64">[64]</xref></p>
      </sec>
      <sec id="article-24306.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24306&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24306">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24306/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24306">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24306.s11">
        <title>References</title>
        <ref id="article-24306.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Beam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Faiella-Tommasino</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lopez-Pajares</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ndumele</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Peralta</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Yeboah</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2019</year>
            <month>Jun</month>
            <day>18</day>
            <volume>139</volume>
            <issue>25</issue>
            <fpage>e1082</fpage>
            <page-range>e1082-e1143</page-range>
            <pub-id pub-id-type="pmid">30586774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sizar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nassereddin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Talati</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Ezetimibe</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">30422474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubins</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Robins</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fye</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Elam</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Faas</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Linares</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Schectman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wilt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wittes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Aug</month>
            <day>05</day>
            <volume>341</volume>
            <issue>6</issue>
            <fpage>410</fpage>
            <page-range>410-8</page-range>
            <pub-id pub-id-type="pmid">10438259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fibrates for secondary prevention of cardiovascular disease and stroke.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Oct</month>
            <day>25</day>
            <volume>2015</volume>
            <issue>10</issue>
            <fpage>CD009580</fpage>
            <pub-id pub-id-type="pmid">26497361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Probstfield</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hunninghake</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Nicotinic acid as a lipoprotein-altering agent. Therapy directed by the primary physician.</article-title>
            <source>Arch Intern Med</source>
            <year>1994</year>
            <month>Jul</month>
            <day>25</day>
            <volume>154</volume>
            <issue>14</issue>
            <fpage>1557</fpage>
            <page-range>1557-9</page-range>
            <pub-id pub-id-type="pmid">8031204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mok</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Zech</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man.</article-title>
            <source>J Lipid Res</source>
            <year>1981</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-36</page-range>
            <pub-id pub-id-type="pmid">7217784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Handelsman</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Role of bile acid sequestrants in the treatment of type 2 diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2011</year>
            <month>May</month>
            <volume>34 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>S244</fpage>
            <page-range>S244-50</page-range>
            <pub-id pub-id-type="pmid">21525463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Cha</surname>
                <given-names>BY</given-names>
              </name>
            </person-group>
            <article-title>Refractory Graves' Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy.</article-title>
            <source>Endocrinol Metab (Seoul)</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>620</fpage>
            <page-range>620-5</page-range>
            <pub-id pub-id-type="pmid">26394731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Albers</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Bisson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>VF</given-names>
              </name>
              <name>
                <surname>Dodge</surname>
                <given-names>HT</given-names>
              </name>
            </person-group>
            <article-title>Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.</article-title>
            <source>N Engl J Med</source>
            <year>1990</year>
            <month>Nov</month>
            <day>08</day>
            <volume>323</volume>
            <issue>19</issue>
            <fpage>1289</fpage>
            <page-range>1289-98</page-range>
            <pub-id pub-id-type="pmid">2215615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knapp</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Schrott</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Knopp</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gaziano</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.</article-title>
            <source>Am J Med</source>
            <year>2001</year>
            <month>Apr</month>
            <day>01</day>
            <volume>110</volume>
            <issue>5</issue>
            <fpage>352</fpage>
            <page-range>352-60</page-range>
            <pub-id pub-id-type="pmid">11286949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <article-title>Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.</article-title>
            <source>Arch Intern Med</source>
            <year>1993</year>
            <month>Jun</month>
            <day>14</day>
            <volume>153</volume>
            <issue>11</issue>
            <fpage>1321</fpage>
            <page-range>1321-9</page-range>
            <pub-id pub-id-type="pmid">8507122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Istvan</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Deisenhofer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Structural mechanism for statin inhibition of HMG-CoA reductase.</article-title>
            <source>Science</source>
            <year>2001</year>
            <month>May</month>
            <day>11</day>
            <volume>292</volume>
            <issue>5519</issue>
            <fpage>1160</fpage>
            <page-range>1160-4</page-range>
            <pub-id pub-id-type="pmid">11349148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ness</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.</article-title>
            <source>Arch Biochem Biophys</source>
            <year>1996</year>
            <month>Jan</month>
            <day>15</day>
            <volume>325</volume>
            <issue>2</issue>
            <fpage>242</fpage>
            <page-range>242-8</page-range>
            <pub-id pub-id-type="pmid">8561503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conde</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vergara-Jimenez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig.</article-title>
            <source>J Lipid Res</source>
            <year>1996</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>2372</fpage>
            <page-range>2372-82</page-range>
            <pub-id pub-id-type="pmid">8978489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Illingworth</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Drug treatment of dyslipoproteinemia.</article-title>
            <source>Med Clin North Am</source>
            <year>1994</year>
            <month>Jan</month>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>225</fpage>
            <page-range>225-45</page-range>
            <pub-id pub-id-type="pmid">8283933</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Troendle</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Fattu</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.</article-title>
            <source>Circulation</source>
            <year>1993</year>
            <month>Apr</month>
            <volume>87</volume>
            <issue>4 Suppl</issue>
            <fpage>III45</fpage>
            <page-range>III45-53</page-range>
            <pub-id pub-id-type="pmid">8462180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bays</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>McKenney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cain</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Blasetto</surname>
                <given-names>JW</given-names>
              </name>
              <collab>STELLAR Study Group</collab>
            </person-group>
            <article-title>Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).</article-title>
            <source>Am J Cardiol</source>
            <year>2003</year>
            <month>Jul</month>
            <day>15</day>
            <volume>92</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-60</page-range>
            <pub-id pub-id-type="pmid">12860216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakker-Arkema</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Davignon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Isaacsohn</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Keilson</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Shurzinske</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.</article-title>
            <source>JAMA</source>
            <year>1996</year>
            <month>Jan</month>
            <day>10</day>
            <volume>275</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-33</page-range>
            <pub-id pub-id-type="pmid">8531308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Altmann</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hoos</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Tetzloff</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Maguire</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Golovko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Murgolo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Graziano</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption.</article-title>
            <source>Science</source>
            <year>2004</year>
            <month>Feb</month>
            <day>20</day>
            <volume>303</volume>
            <issue>5661</issue>
            <fpage>1201</fpage>
            <page-range>1201-4</page-range>
            <pub-id pub-id-type="pmid">14976318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Temel</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rudel</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Willingham</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ioannou</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe.</article-title>
            <source>J Clin Invest</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>117</volume>
            <issue>7</issue>
            <fpage>1968</fpage>
            <page-range>1968-78</page-range>
            <pub-id pub-id-type="pmid">17571164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Packard</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Third</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lawrie</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>The effects of cholestyramine on high density lipoprotein metabolism.</article-title>
            <source>Atherosclerosis</source>
            <year>1979</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>433</fpage>
            <page-range>433-44</page-range>
            <pub-id pub-id-type="pmid">228682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davidson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Isaacsohn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.</article-title>
            <source>Arch Intern Med</source>
            <year>1999</year>
            <month>Sep</month>
            <day>13</day>
            <volume>159</volume>
            <issue>16</issue>
            <fpage>1893</fpage>
            <page-range>1893-900</page-range>
            <pub-id pub-id-type="pmid">10493319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mullard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol-lowering blockbuster candidates speed into Phase III trials.</article-title>
            <source>Nat Rev Drug Discov</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>817</fpage>
            <page-range>817-9</page-range>
            <pub-id pub-id-type="pmid">23123928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miettinen</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Diurnal variation of cholesterol precursors squalene and methyl sterols in human plasma lipoproteins.</article-title>
            <source>J Lipid Res</source>
            <year>1982</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>466</fpage>
            <page-range>466-73</page-range>
            <pub-id pub-id-type="pmid">7200504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Backes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Venero</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Ruisinger</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.</article-title>
            <source>Ann Pharmacother</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-6</page-range>
            <pub-id pub-id-type="pmid">18285559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kayik&#x000e7;io&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ozerkan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Soydan</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia.</article-title>
            <source>Am J Cardiol</source>
            <year>1999</year>
            <month>Apr</month>
            <day>01</day>
            <volume>83</volume>
            <issue>7</issue>
            <fpage>1135</fpage>
            <page-range>1135-7, A9</page-range>
            <pub-id pub-id-type="pmid">10190536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruisinger</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Backes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Moriarty</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.</article-title>
            <source>Am J Cardiol</source>
            <year>2009</year>
            <month>Feb</month>
            <day>01</day>
            <volume>103</volume>
            <issue>3</issue>
            <fpage>393</fpage>
            <page-range>393-4</page-range>
            <pub-id pub-id-type="pmid">19166695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenson</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kopecky</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>The National Lipid Association's Muscle Safety Expert Panel</surname>
              </name>
            </person-group>
            <article-title>An assessment by the Statin Muscle Safety Task Force: 2014 update.</article-title>
            <source>J Clin Lipidol</source>
            <year>2014</year>
            <season>May-Jun</season>
            <volume>8</volume>
            <issue>3 Suppl</issue>
            <fpage>S58</fpage>
            <page-range>S58-71</page-range>
            <pub-id pub-id-type="pmid">24793443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stroes</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Corsini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vladutiu</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Raal</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Roden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tokg&#x000f6;zo&#x0011f;lu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Bruckert</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Backer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Krauss</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Laufs</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hovingh</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Mach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>M&#x000e4;rz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Wiklund</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>HN</given-names>
              </name>
              <collab>European Atherosclerosis Society Consensus Panel</collab>
            </person-group>
            <article-title>Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.</article-title>
            <source>Eur Heart J</source>
            <year>2015</year>
            <month>May</month>
            <day>01</day>
            <volume>36</volume>
            <issue>17</issue>
            <fpage>1012</fpage>
            <page-range>1012-22</page-range>
            <pub-id pub-id-type="pmid">25694464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenson</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Current overview of statin-induced myopathy.</article-title>
            <source>Am J Med</source>
            <year>2004</year>
            <month>Mar</month>
            <day>15</day>
            <volume>116</volume>
            <issue>6</issue>
            <fpage>408</fpage>
            <page-range>408-16</page-range>
            <pub-id pub-id-type="pmid">15006590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganga</surname>
                <given-names>HV</given-names>
              </name>
              <name>
                <surname>Slim</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of statin-induced muscle problems in clinical trials.</article-title>
            <source>Am Heart J</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>168</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-15</page-range>
            <pub-id pub-id-type="pmid">24952854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joy</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Narrative review: statin-related myopathy.</article-title>
            <source>Ann Intern Med</source>
            <year>2009</year>
            <month>Jun</month>
            <day>16</day>
            <volume>150</volume>
            <issue>12</issue>
            <fpage>858</fpage>
            <page-range>858-68</page-range>
            <pub-id pub-id-type="pmid">19528564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Capizzi</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Grimaldi</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Clarkson</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Keadle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chipkin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pescatello</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Effect of statins on skeletal muscle function.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Jan</month>
            <day>01</day>
            <volume>127</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-103</page-range>
            <pub-id pub-id-type="pmid">23183941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tobert</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and long-term adverse effect pattern of lovastatin.</article-title>
            <source>Am J Cardiol</source>
            <year>1988</year>
            <month>Nov</month>
            <day>11</day>
            <volume>62</volume>
            <issue>15</issue>
            <fpage>28J</fpage>
            <page-range>28J-34J</page-range>
            <pub-id pub-id-type="pmid">3055921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Faergeman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Haghfelt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kjekshus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miettinen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Musliner</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Py&#x000f6;r&#x000e4;l&#x000e4;</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Thorgeirsson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tobert</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wedel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wilhelmsen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.</article-title>
            <source>Arch Intern Med</source>
            <year>1996</year>
            <month>Oct</month>
            <day>14</day>
            <volume>156</volume>
            <issue>18</issue>
            <fpage>2085</fpage>
            <page-range>2085-92</page-range>
            <pub-id pub-id-type="pmid">8862101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gadbut</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Caruso</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Galper</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.</article-title>
            <source>J Mol Cell Cardiol</source>
            <year>1995</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>2397</fpage>
            <page-range>2397-402</page-range>
            <pub-id pub-id-type="pmid">8576954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zinman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sadeghi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gawel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Are statin medications safe in patients with ALS?</article-title>
            <source>Amyotroph Lateral Scler</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>223</fpage>
            <page-range>223-8</page-range>
            <pub-id pub-id-type="pmid">18608105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Bannykh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hathaway</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Vladutiu</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>England</surname>
                <given-names>JD</given-names>
              </name>
              <collab>Scripps Mercy Clinical Research Center</collab>
            </person-group>
            <article-title>Statin-associated myopathy with normal creatine kinase levels.</article-title>
            <source>Ann Intern Med</source>
            <year>2002</year>
            <month>Oct</month>
            <day>01</day>
            <volume>137</volume>
            <issue>7</issue>
            <fpage>581</fpage>
            <page-range>581-5</page-range>
            <pub-id pub-id-type="pmid">12353945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Rind</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Shmerling</surname>
                <given-names>RH</given-names>
              </name>
            </person-group>
            <article-title>Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.</article-title>
            <source>Arch Intern Med</source>
            <year>2003</year>
            <month>Mar</month>
            <day>24</day>
            <volume>163</volume>
            <issue>6</issue>
            <fpage>688</fpage>
            <page-range>688-92</page-range>
            <pub-id pub-id-type="pmid">12639201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weismantel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Danis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?</article-title>
            <source>J Fam Pract</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>11</issue>
            <fpage>927</fpage>
            <page-range>927-8</page-range>
            <pub-id pub-id-type="pmid">11711005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gotto</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Safety and statin therapy: reconsidering the risks and benefits.</article-title>
            <source>Arch Intern Med</source>
            <year>2003</year>
            <month>Mar</month>
            <day>24</day>
            <volume>163</volume>
            <issue>6</issue>
            <fpage>657</fpage>
            <page-range>657-9</page-range>
            <pub-id pub-id-type="pmid">12639194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenson</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bayliss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Baccara-Dinet</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Chibedi-De-Roche</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Manvelian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability.</article-title>
            <source>Cardiovasc Drugs Ther</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-186</page-range>
            <pub-id pub-id-type="pmid">28421332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serban</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sahebkar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ursoniu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rysz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glasser</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Dragan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mikhailidis</surname>
                <given-names>DP</given-names>
              </name>
              <collab>Lipid and Blood Pressure Meta-analysis Collaboration Group</collab>
            </person-group>
            <article-title>Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>90</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-34</page-range>
            <pub-id pub-id-type="pmid">25440725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Illingworth</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Mitchel</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Dujovne</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Frost</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Knopp</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Tun</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zupkis</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Greguski</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.</article-title>
            <source>Arch Intern Med</source>
            <year>1994</year>
            <month>Jul</month>
            <day>25</day>
            <volume>154</volume>
            <issue>14</issue>
            <fpage>1586</fpage>
            <page-range>1586-95</page-range>
            <pub-id pub-id-type="pmid">8031206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vega</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>McGovern</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Tulloch</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Kendall</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Fitz-Patrick</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ganda</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Rosenson</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>JP</given-names>
              </name>
              <collab>Diabetes Multicenter Research Group</collab>
            </person-group>
            <article-title>Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.</article-title>
            <source>Arch Intern Med</source>
            <year>2002</year>
            <month>Jul</month>
            <day>22</day>
            <volume>162</volume>
            <issue>14</issue>
            <fpage>1568</fpage>
            <page-range>1568-76</page-range>
            <pub-id pub-id-type="pmid">12123399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasternak</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Kolman</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Unstable myocardial ischemia after the initiation of niacin therapy.</article-title>
            <source>Am J Cardiol</source>
            <year>1991</year>
            <month>Apr</month>
            <day>15</day>
            <volume>67</volume>
            <issue>9</issue>
            <fpage>904</fpage>
            <page-range>904-6</page-range>
            <pub-id pub-id-type="pmid">2011995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Malinow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pettinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Upson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hunninghake</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Niacin treatment increases plasma homocyst(e)ine levels.</article-title>
            <source>Am Heart J</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>138</volume>
            <issue>6 Pt 1</issue>
            <fpage>1082</fpage>
            <page-range>1082-7</page-range>
            <pub-id pub-id-type="pmid">10577438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robinson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Farnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krempf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bergeron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luc</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Averna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stroes</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Langslet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Raal</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>El Shahawy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lepor</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Lorenzato</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pordy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chaudhari</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <collab>ODYSSEY LONG TERM Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Apr</month>
            <day>16</day>
            <volume>372</volume>
            <issue>16</issue>
            <fpage>1489</fpage>
            <page-range>1489-99</page-range>
            <pub-id pub-id-type="pmid">25773378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Raal</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Blom</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Somaratne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Legg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>EA</given-names>
              </name>
              <collab>Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Apr</month>
            <day>16</day>
            <volume>372</volume>
            <issue>16</issue>
            <fpage>1500</fpage>
            <page-range>1500-9</page-range>
            <pub-id pub-id-type="pmid">25773607</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>QQ</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>QH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.</article-title>
            <source>BMC Med</source>
            <year>2015</year>
            <month>Jun</month>
            <day>23</day>
            <volume>13</volume>
            <fpage>123</fpage>
            <pub-id pub-id-type="pmid">26099511</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vahedian-Azimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Makvandi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Banach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>&#x0017d;</given-names>
              </name>
              <name>
                <surname>Sahebkar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Fetal toxicity associated with statins: A systematic review and meta-analysis.</article-title>
            <source>Atherosclerosis</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>327</volume>
            <fpage>59</fpage>
            <page-range>59-67</page-range>
            <pub-id pub-id-type="pmid">34044205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lees</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Lees</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole.</article-title>
            <source>N Engl J Med</source>
            <year>1995</year>
            <month>Sep</month>
            <day>07</day>
            <volume>333</volume>
            <issue>10</issue>
            <fpage>664</fpage>
            <page-range>664-5</page-range>
            <pub-id pub-id-type="pmid">7637734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fichtenbaum</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Aberg</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Blaschke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Alston</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kosel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aweeka</surname>
                <given-names>F</given-names>
              </name>
              <collab>NIAID AIDS Clinical Trials Group</collab>
            </person-group>
            <article-title>Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.</article-title>
            <source>AIDS</source>
            <year>2002</year>
            <month>Mar</month>
            <day>08</day>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>569</fpage>
            <page-range>569-77</page-range>
            <pub-id pub-id-type="pmid">11873000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKenney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>JR</given-names>
              </name>
              <collab>National Lipid Association Statin Safety Assessment Task Force</collab>
            </person-group>
            <article-title>Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.</article-title>
            <source>Am J Cardiol</source>
            <year>2006</year>
            <month>Apr</month>
            <day>17</day>
            <volume>97</volume>
            <issue>8A</issue>
            <fpage>89C</fpage>
            <page-range>89C-94C</page-range>
            <pub-id pub-id-type="pmid">16581336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>NLA Task Force on Statin Safety--2014 update.</article-title>
            <source>J Clin Lipidol</source>
            <year>2014</year>
            <season>May-Jun</season>
            <volume>8</volume>
            <issue>3 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-4</page-range>
            <pub-id pub-id-type="pmid">24793438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Bairey Merz</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Eckel</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shero</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Eddleman</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Jarrett</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>LaBresh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nevo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wnek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pressler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sellke</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tomaselli</surname>
                <given-names>GF</given-names>
              </name>
              <collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Jun</month>
            <day>24</day>
            <volume>129</volume>
            <issue>25 Suppl 2</issue>
            <fpage>S1</fpage>
            <page-range>S1-45</page-range>
            <pub-id pub-id-type="pmid">24222016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gurk-Turner</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Ezetimibe (Zetia): a new type of lipid-lowering agent.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2003</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>354</fpage>
            <page-range>354-8</page-range>
            <pub-id pub-id-type="pmid">16278712</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Armani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKenney</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Safety considerations with gastrointestinally active lipid-lowering drugs.</article-title>
            <source>Am J Cardiol</source>
            <year>2007</year>
            <month>Mar</month>
            <day>19</day>
            <volume>99</volume>
            <issue>6A</issue>
            <fpage>47C</fpage>
            <page-range>47C-55C</page-range>
            <pub-id pub-id-type="pmid">17368279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Amess</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of hypertriglyceridemia in the diabetic patient.</article-title>
            <source>Curr Diab Rep</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>316</fpage>
            <page-range>316-20</page-range>
            <pub-id pub-id-type="pmid">20532703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Keech</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Honarpour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kuder</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <collab>FOURIER Steering Committee and Investigators</collab>
            </person-group>
            <article-title>Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>04</day>
            <volume>376</volume>
            <issue>18</issue>
            <fpage>1713</fpage>
            <page-range>1713-1722</page-range>
            <pub-id pub-id-type="pmid">28304224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Blazing</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>McCagg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Theroux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Darius</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Ophuis</surname>
                <given-names>TO</given-names>
              </name>
              <name>
                <surname>Jukema</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>De Ferrari</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Ruzyllo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>De Lucca</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bohula</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Reist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Tershakovec</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Musliner</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
              <collab>IMPROVE-IT Investigators</collab>
            </person-group>
            <article-title>Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Jun</month>
            <day>18</day>
            <volume>372</volume>
            <issue>25</issue>
            <fpage>2387</fpage>
            <page-range>2387-97</page-range>
            <pub-id pub-id-type="pmid">26039521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Houri</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Notarbartolo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Melani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lipka</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Suresh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>LeBeaut</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Sager</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Veltri</surname>
                <given-names>EP</given-names>
              </name>
              <collab>Ezetimibe Study Group</collab>
            </person-group>
            <article-title>Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.</article-title>
            <source>Circulation</source>
            <year>2003</year>
            <month>May</month>
            <day>20</day>
            <volume>107</volume>
            <issue>19</issue>
            <fpage>2409</fpage>
            <page-range>2409-15</page-range>
            <pub-id pub-id-type="pmid">12719279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Ketchum</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Juliano</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Granowitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tardif</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <collab>REDUCE-IT Investigators</collab>
            </person-group>
            <article-title>Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jan</month>
            <day>03</day>
            <volume>380</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-22</page-range>
            <pub-id pub-id-type="pmid">30415628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24306.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Christen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bassuk</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Copeland</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>D'Agostino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Friedenberg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ridge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bubes</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Giovannucci</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Buring</surname>
                <given-names>JE</given-names>
              </name>
              <collab>VITAL Research Group</collab>
            </person-group>
            <article-title>Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Jan</month>
            <day>03</day>
            <volume>380</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-32</page-range>
            <pub-id pub-id-type="pmid">30415637</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
